𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Using purified P-glycoprotein to understand multidrug resistance

✍ Scribed by Adam B. Shapiro; Victor Ling

Publisher
Springer US
Year
1995
Tongue
English
Weight
641 KB
Volume
27
Category
Article
ISSN
0145-479X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Multidrug resistance genes, p-glycoprote
Multidrug resistance genes, p-glycoprotein and the liver
✍ Dr. Irwin M. Arias πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 819 KB

Clinicians have long observed that treatment with one anticancer drug can confer resistance to that drug and to other anticancer drugs with different chemical structures and mechanisms of action. This is the multidrug resistance (MDR) phenomenon, which frequently occurs in the absence of previous ch

Overcoming tumor multidrug resistance us
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression
✍ Stefania Nobili; Ida Landini; Teresita Mazzei; Enrico Mini πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 403 KB

## Abstract Multidrug resistance (MDR) is a major obstacle to the effective treatment of cancer. Cellular overproduction of P‐glycoprotein (P‐gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer ant

Molecular basis of multidrug resistance
Molecular basis of multidrug resistance mediated by P-glycoprotein
✍ Christopher F. Higgins πŸ“‚ Article πŸ“… 1991 πŸ› Elsevier Science 🌐 English βš– 381 KB

In the past year, our understanding of the biology and molecular basis of multidrug resistance of tumours has advanced on several fronts. Intriguing clues to some of the key questions in the area provide optimism for future understanding and, with luck, eventual prevention and/or treatment.